ALQGC.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 10:57):

Stats
Today's Volume	7 367.00
Average Volume	119 099
Market Cap	3.97M
EPS	€0 ( 2023-10-23 )
Next earnings date	( €0 ) 2024-05-26
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.140
ATR14	€0.00200 (1.74%)

Quantum Genomics SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Quantum Genomics SA Financials

Annual	2023
Revenue:	€10 060.00
Gross Profit:	€-3.02M (-29 979.73 %)
EPS:	€-0.0919

Q4	2023
Revenue:	€0
Gross Profit:	€-3 845.00 (0.00 %)
EPS:	€-0.0344

Q2	2023
Revenue:	€10 060.00
Gross Profit:	€-1.94M (-19 250.90 %)
EPS:	€-0.0576

Q4	2022
Revenue:	€402 065
Gross Profit:	€-17.11M (-4 255.84 %)
EPS:	€-0.320

Financial Reports:

No articles found.

Quantum Genomics SA

Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.